沃森生物：签署微生态健康靶向技术独家再许可协议之修正案 扩大合作范围至非患者领域

Core Points - Watson Bio announced a board meeting on July 30, 2025, to approve a revised agreement that expands the scope of "core microbiome therapy" into precision microbiome health and functional nutrition intervention [1] - The revision includes granting exclusive rights for development, manufacturing, and commercialization in mainland China, Hong Kong, and Macau for non-patient populations [1] - The financial terms, duration, and due diligence clauses of the agreement have been amended, but the signing will not significantly impact the company's operating performance for the current year [1]